EQRx Worth $3.65B In Deal Led By Goodwin, White & Case
EQRx, a life science company focused on lowering drug costs for serious diseases, will go public at a $3.65 billion enterprise value by merging with a private equity-backed special purpose acquisition...To view the full article, register now.
Already a subscriber? Click here to view full article